What changed in Elanco Animal Health Incorporated's latest annual report
In the year ended 31 Dec 2025, Elanco Animal Health Incorporated's revenue rose 6.2% to USD 4.71bn, from USD 4.44bn; cash and cash equivalents rose 16.5% to USD 545.00m, from USD 468.00m; long-term debt fell 12.9% to USD 3.76bn, from USD 4.32bn.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 4.44bn to USD 4.71bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 4.44bn | 4.71bn | Up 6.2% |
| Net income | 338.00m | -232.00m | Not comparable |
| Total assets | 12.61bn | 13.36bn | Up 5.9% |
| Total liabilities | 6.52bn | 6.81bn | Up 4.5% |
| Long-term debt | 4.32bn | 3.76bn | Down 12.9% |
| Cash and cash equivalents | 468.00m | 545.00m | Up 16.5% |
| Shareholders' equity | 6.10bn | 6.55bn | Up 7.4% |
Questions people ask
Did Elanco Animal Health Incorporated's revenue grow last year?
Revenue grew 6.2%, from USD 4.44bn to USD 4.71bn in the year ended 31 Dec 2025.
Is Elanco Animal Health Incorporated profitable?
Not in its latest year: it reported a net loss of USD 232.00m in the year ended 31 Dec 2025. The year before: USD 338.00m.
How much cash and debt does Elanco Animal Health Incorporated have?
At its latest year end (31 Dec 2025), Elanco Animal Health Incorporated reported cash and cash equivalents of USD 545.00m and long-term debt of USD 3.76bn.
Where do these numbers come from?
From Elanco Animal Health Incorporated's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Elanco Animal Health Incorporated?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%